CLAIMS

1. An agent for treating pancreatic cancer, which comprises an anti-interleukin 6 (IL-6) receptor antibody as an active ingredient.

2. An agent for suppressing neural invasion of a cell, which comprises an anti-IL-6 receptor antibody as an active ingredient.

3. The agent of claim 2, which suppresses neural invasion of a cancer cell.

4. The agent of claim 3, which suppresses neural invasion of a pancreatic cancer cell.

5. The agent of any one of claims 2 to 4, which suppresses neural invasion in the central direction.

6. The agent of any one of claims 1 to 5, wherein the anti-IL-6 receptor antibody is a substance that binds to an IL-6 receptor.

7. The agent of claim 1, wherein the anti-IL-6 receptor antibody is a chimeric, humanized, or human antibody.

8. Use of an anti-IL-6 receptor antibody in the production of an agent for treating pancreatic cancer.

9. Use of an anti-IL-6 receptor antibody in the production of an agent for suppressing neural invasion of a cell.

10. The use of claim 9, wherein neural invasion of a cancer cell is suppressed.

11. The use of claim 10, wherein neural invasion of a pancreatic cancer cell is suppressed.

12. The use of any one of claims 9 to 11, wherein neural invasion in the central direction is suppressed.

13. The use of claims 8 to 12, wherein the anti-IL-6 receptor antibody is a substance that binds to an IL-6 receptor.

14. The use of claim 13, wherein the anti-IL-6 receptor antibody is a chimeric, humanized, or human antibody.

15. An anti-IL-6 receptor antibody for use in a method for treating pancreatic cancer.

16. An anti-IL-6 receptor antibody for use in a method for suppressing neural invasion of a cell.

17. The anti-IL-6 receptor antibody of claim 16, which suppresses neural invasion of a cancer cell.

18. The anti-IL-6 receptor antibody of claim 17, which suppresses neural invasion of a pancreatic cancer cell.

19. The anti-IL-6 receptor antibody of any one of claims 16 to 18, which suppresses neural invasion in the central direction.

20. The anti-IL-6 receptor antibody of any one of claims 15 to 19, wherein the anti-IL-6 receptor antibody is a substance that binds to an IL-6 receptor.

21. The anti-IL-6 receptor antibody of claim 20, wherein the anti-IL-6 receptor antibody is a chimeric, humanized, or human antibody.

CLAIMS

1. Use of an anti-IL-6 receptor antibody in the production of an agent for suppressing neural invasion of a pancreatic cancer cell.

2. The use of claim 1, wherein neural invasion in the central direction is suppressed.

3. The use of any one of claims 1 to 2, wherein the anti-IL-6 receptor antibody is a chimeric, humanized, or human antibody.